New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 30, 2025 - Axsome Therapeutics announced the FDA approval of Symbravo (meloxicam/rizatriptan), for the acute treatment of migraine with or without aura in adults.
Download PDF
Return to publications
